


Details:
The company’s first microbial product, “Ensemble No.2” (ENS-002), is designed to rehabilitate the skin microbiome. By taming the pathogenic behaviors of Staphylococcus aureus, ENS-002 may decrease the frequency and severity of eczema flares.
Lead Product(s): ENS-002
Therapeutic Area: Dermatology Product Name: ENS-002
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Safar Partners
Deal Size: $23.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 02, 2022
Details:
The collaboration aims to generate and develop NanoAbs with the potential to answering needs underserved by currently approved conventional monoclonal antibody therapeutics as the NanoAbs exhibit potential for patient convenience, safety, and clinical outcomes, at lower costs.
Lead Product(s): Alpaca‑derived Nanosized Antibody
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Max Planck Institute for Multidisciplinary Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 20, 2022
Details:
LEO Pharma will leverage insights generated under this collaboration to build robust evidence in support of new potential approaches that significantly impact dermatologic conditions.
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Leo Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 07, 2022
Details:
The funds will support Revel as it advances its repair-based enzyme therapy pipeline towards the clinic. Enzymes are applied therapeutically in only a handful of applications, including for wrinkle treatment (Botox), cancer (Asparaginase), and cystic fibrosis (DNase).
Lead Product(s): Enzyme Therapy
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Kizoo Technology Capital
Deal Size: $8.4 million Upfront Cash: Undisclosed
Deal Type: Financing March 17, 2022
Details:
The financing will allow to advance four programs of Evommune in pipeline among which three of the compounds include IRAK4/TrkA, broadly inhibits innate inflammation; RORγt, treating inflammation; MRGPRX2, to treat chronic pruritus and fourth compound is a PKCtheta inhibitor.
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Andera Partners
Deal Size: $83.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 09, 2021
Details:
Eligo will receive an upfront payment and R&D funding to advance EB005, until preclinical proof of concept. If GSK exercises its option, GSK and Eligo will enter into a license and collaboration agreement to jointly continue the development of EB005 in acne.
Lead Product(s): EB005
Therapeutic Area: Dermatology Product Name: EB005
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: GSK
Deal Size: $224.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 11, 2021
Details:
The collaboration aim to develop a novel class of medicines that target and degrade disease-causing proteins. The novel mechanism of action of PROTACs generates the possibility to eliminate disease relevant targets that were difficult to tackle with conventional approaches.
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: University of Dundee
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 08, 2020
Details:
Open Innovation Agreement with LEO Pharma A/S will screen novel VAP-1 inhibitor compounds discovered by Kubota Vision.
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Kubota Vision Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 16, 2020